Clinical Trial Update: Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating afatinib plus paclitaxel in advanced HER2-positive, trastuzumab-refractory esophagogastric cancer has completed with results p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Gastric Cancer

Drugs mentioned

• Afatinib (afatinib)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Esophageal Cancer, Gastric Cancer | Phase 2 | Status: COMPLETED | Results posted: 2023-11-01